Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Induced Pluripotent Stem Cells Recovered from Urine

By BiotechDaily International staff writers
Posted on 14 Apr 2017
Print article
Image: Three copies of chromosome 21 characterize the karyotype for trisomy Down syndrome (Photo courtesy of Wikimedia Commons).
Image: Three copies of chromosome 21 characterize the karyotype for trisomy Down syndrome (Photo courtesy of Wikimedia Commons).
Urine from individuals with Down syndrome has been utilized as a source of cells, which researchers first transformed into stem cells and then induced to mature into neurons and heart cells.

Investigators at Case Western Reserve University described in the March 28, 2017, online edition of the journal Stem Cells Translational Medicine the method by which they had generated 10 induced pluripotent stem cell (iPSC) lines from epithelial cells recovered from urine samples obtained from individuals with Down syndrome. These cells were presumably of kidney epithelial origin, and were induced using nonintegrating episomal vectors. Episomal vectors offered many advantages over integrating vectors as they eliminated non-specific integration into the host genome and with that eliminated the risk of transformation.

The investigators showed that these Down syndrome iPSCs maintained chromosomal stability for well over 20 passages and were more sensitive to proteotoxic stress than iPSCs with normal chromosome number. Furthermore, these iPSC lines could be differentiated into glutamatergic neurons and cardiomyocytes.

“For the first time, we were able to create induced pluripotent stem cells, or iPSCs, of persons with Down syndrome by cells obtained from urine samples,” said senior author Dr. Alberto Costa, professor of pediatrics and psychiatry at Case Western Reserve University. “Our methods represent a significant improvement in iPSC technology, and should be an important step toward the development of human cell-based platforms that can be used to test new medications designed to improve the quality of life of people with Down syndrome.”


Print article

Channels

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2017 Globetech Media. All rights reserved.